Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2341
mi
from 98109
Pottstown, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2341
mi
from 98109
Pottstown, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2351
mi
from 98109
Red Lion, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2351
mi
from 98109
Red Lion, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2298
mi
from 98109
Wilkes-Barre, PA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2298
mi
from 98109
Wilkes-Barre, PA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2484
mi
from 98109
Cumberland, RI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2484
mi
from 98109
Cumberland, RI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2321
mi
from 98109
Columbia, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2321
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2227
mi
from 98109
Greenville, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2227
mi
from 98109
Greenville, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2231
mi
from 98109
Greer, SC
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2231
mi
from 98109
Greer, SC
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2152
mi
from 98109
Greeneville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2152
mi
from 98109
Greeneville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2113
mi
from 98109
Knoxville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2029
mi
from 98109
Tullahoma, TN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2029
mi
from 98109
Tullahoma, TN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1916
mi
from 98109
Corpus Christi, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1916
mi
from 98109
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1729
mi
from 98109
Kerrville, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 98109
Kerrville, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1882
mi
from 98109
Kingwood, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1882
mi
from 98109
Kingwood, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1790
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1863
mi
from 98109
Tomball, TX
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1863
mi
from 98109
Tomball, TX
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
696
mi
from 98109
Bountiful, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
696
mi
from 98109
Bountiful, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
706
mi
from 98109
Murray, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
706
mi
from 98109
Murray, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
701
mi
from 98109
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2285
mi
from 98109
Charlottesville, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2285
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2293
mi
from 98109
Danville, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2293
mi
from 98109
Danville, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2316
mi
from 98109
Falls Church, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2316
mi
from 98109
Falls Church, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2252
mi
from 98109
Harrisonburg, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2252
mi
from 98109
Harrisonburg, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2277
mi
from 98109
Lynchburg, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2277
mi
from 98109
Lynchburg, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2246
mi
from 98109
Roanoke, VA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2246
mi
from 98109
Roanoke, VA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
9
mi
from 98109
Bellevue, WA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
9
mi
from 98109
Bellevue, WA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
26
mi
from 98109
Tacoma, WA
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
26
mi
from 98109
Tacoma, WA
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2087
mi
from 98109
Huntington, WV
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2087
mi
from 98109
Huntington, WV
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1646
mi
from 98109
Green Bay, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1646
mi
from 98109
Green Bay, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1616
mi
from 98109
Madison, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1616
mi
from 98109
Madison, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1621
mi
from 98109
Oregon, WI
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1621
mi
from 98109
Oregon, WI
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from 98109
Belgrano,
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from 98109
Belgrano,
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1337
mi
from 98109
Saint Cloud, MN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1337
mi
from 98109
Saint Cloud, MN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1400
mi
from 98109
Saint Paul, MN
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1400
mi
from 98109
Saint Paul, MN
Click here to add this to my saved trials
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
A Study of Evacetrapib in High-Risk Vascular Disease
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1720
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques
Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention
Status: Enrolling
Updated:  12/31/1969
Spectrum Health; Frederik Meijer Heart &Vascular Institute
1796
mi
from 98109
Grand Rapids, MI
Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques
Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention
Status: Enrolling
Updated: 12/31/1969
Spectrum Health; Frederik Meijer Heart &Vascular Institute
1796
mi
from 98109
Grand Rapids, MI
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
Manhattan VA Hospital
2262
mi
from 98109
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
Manhattan VA Hospital
2262
mi
from 98109
New York, NY
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
Bellevue Hospital Center
2402
mi
from 98109
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
Bellevue Hospital Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated:  12/31/1969
New York Langone Medical Center
2401
mi
from 98109
New York, NY
Anti-inflammatory Effects of Colchicine in PCI
Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention
Status: Enrolling
Updated: 12/31/1969
New York Langone Medical Center
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2038
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2151
mi
from 98109
Mobile, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2151
mi
from 98109
Mobile, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2151
mi
from 98109
Mobile, AL
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2151
mi
from 98109
Mobile, AL
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1220
mi
from 98109
Tucson, AZ
Click here to add this to my saved trials